In English | En español
Questions About Cancer? 1-800-4-CANCER

Find News Releases

Search For:
Between these dates:

All News Releases

Dana-Farber study suggests that expanded health coverage may improve cancer outcomes in young adults
NCI Cancer Center News
(Posted: 06/03/2014) - Researchers find young adults who lack health care insurance are more likely to be diagnosed in advanced stages of cancer and have a higher risk of death.

Huntsman researchers find that reduced kidney function is associated with higher risk of renal and urothelial cancer
NCI Cancer Center News
(Posted: 06/02/2014) - Researchers who investigated the level of kidney function and subsequent cancer risk in more than one million adults have found that reduced glomerular filtration rate is a key measure of reduced kidney function and chronic kidney disease is an independent risk factor for renal and urothelial cancer but not other cancer types.

Duke researchers identify new brain cancer mutation that will aid drug development
NCI Cancer Center News
(Posted: 06/02/2014) - A collaborative effort between Duke Medicine researchers and neurosurgeons and scientists in China has produced new genetic insights into a rare and deadly form of childhood and young adult brain cancer called brainstem glioma.

NCI at ASCO: A brief overview on research in women's cancers
NCI Perspective Article
(Posted: 06/02/2014) - The 2014 annual American Society of Clinical Oncology (ASCO) meeting in Chicago in June highlighted results from a number of NCI-supported and -sponsored clinical trial results in women’s cancers. Taken together, these results represent important advances in our understanding of how to treat these diseases and improve the lives of those living with them.
View the article in Spanish

New treatment option for young women with hormone-sensitive breast cancer
NCI Press Release
(Posted: 06/01/2014) - A drug used for treating breast cancer, known as exemestane, is more effective than a common breast cancer prevention drug, tamoxifen, in preventing breast cancer recurrence in young women who also receive post-surgical treatment to suppress ovarian function. The combined results of the Tamoxifen and Exemestane Trial and Suppression of Ovarian Function Trial were presented at the 2014 ASCO Annual Meeting in Chicago.
View the article in Spanish

NIH-funded study shows increased survival in men with metastatic prostate cancer who receive chemotherapy when starting hormone therapy
NCI Press Release
(Posted: 12/05/2013, Updated: 06/01/2014) - Men with hormone-sensitive metastatic prostate cancer who received the chemotherapy drug docetaxel given at the start of standard hormone therapy lived longer than patients who received hormone therapy alone, according to early results from a NIH-supported randomized controlled clinical trial.
View the article in Spanish

Study of targeted therapies for breast cancer established model for global clinical trials
(Posted: 02/29/2008, Updated: 06/01/2014) - Two targeted medications designed to treat an aggressive form of breast cancer were tested in a study that involved 8,000 participants in 44 countries. While the purpose of this trial was to enable researchers to determine whether dual targeted treatment of early stage HER2-positive breast cancer was better than using a single agent against HER2-positive disease, results of this trial did not show a benefit for women taking the drug combination of trastuzumab or lapatinib. The trial however, did provide a new model for global cancer research and collaboration.
Questions & Answers Play video View the article in Spanish

Clinical trial analysis suggests drug combination may be highly effective in recurrent ovarian cancer
NCI Press Release
(Posted: 05/31/2014) - Significant improvement with the use of a combination drug therapy for recurrent ovarian cancer was reported at the annual meeting of the American Society of Clinical Oncology meeting in Chicago. The trial compared the activity of a combination of the drug olaparib and the blood vessel inhibitor drug cediranib vs. olaparib alone. Trial results showed a near doubling of progression-free survival benefit for the combination therapy over use of the single drug alone.
View the article in Spanish

Treatment helps young women preserve their fertility during breast cancer chemotherapy
NCI Press Release
(Posted: 05/30/2014) - Researchers have found that young women with breast cancer were able to better preserve their fertility during cancer treatments by using hormone-blocking drug injections that put them into temporary menopause. The results announced today at the annual meeting of the American Society of Clinical Oncology in Chicago are from the Prevention of Early Menopause Study (POEMS), a clinical trial sponsored by NCI.
View the article in Spanish

Tiny mutation triggers drug resistance for patients with one type of leukemia
NCI Cancer Center News
(Posted: 05/29/2014) - A multi-institutional team of researchers has pinpointed exactly what goes wrong when chronic lymphocytic leukemia (CLL) patients develop resistance to ibrutinib, a highly effective, precisely targeted anti-cancer drug. In a correspondence published online May 28 in the New England Journal of Medicine, they show how the mutation triggers resistance.

< Previous  6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26  Next >